Anti-ARA9 antibody - Carboxyterminal end (ab62813)
- Product nameAnti-ARA9 antibody - Carboxyterminal endSee all ARA9 primary antibodies ...
- DescriptionGoat polyclonal to ARA9 - Carboxyterminal end
- Tested applicationsWB, ELISA more details
- Species reactivityReacts with: Mouse
Predicted to work with: Rat, Horse, Cow, Human
Synthetic peptide: C-EARIRQKDEEDKAR, corresponding to C terminal amino acids 310-323 of Human ARA9
- Positive control
- NIH 3T3 cell lysates.
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
- Storage bufferPreservative: 0.02% Sodium Azide
Constituents: 0.5% BSA, Tris buffered saline, pH 7.3
- Concentration information loading...
- PurityImmunogen affinity purified
- Purification notesab62813 is purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
- Clonality Polyclonal
- Research Areas
Our Abpromise guarantee covers the use of ab62813 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: Use at a concentration of 0.02 - 0.06 µg/ml. Detects a band of approximately 37 kDa (predicted molecular weight: 40 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
- FunctionMay play a positive role in AHR-mediated (aromatic hydrocarbon receptor) signaling, possibly by influencing its receptivity for ligand and/or its nuclear targeting.
Cellular negative regulator of the hepatitis B virus (HBV) X protein.
- Tissue specificityWidely expressed. Higher levels seen in the heart, placenta and skeletal muscle. Not expressed in the liver.
- Involvement in diseaseDefects in AIP are a cause of familial isolated pituitary adenoma (FIPA) [MIM:102200].
Defects in AIP are a cause of growth hormone-secreting pituitary adenoma (GHSPA) [MIM:102200]; also known as familial isolated somatotropinomas (FIS) or isolated familial somatotropinoma (IFS) or familial somatotrophinoma or acromegaly due to pituitary adenoma.
Defects in AIP are a cause of ACTH-secreting pituitary adenoma (ASPA) [MIM:219090]; also known as pituitary Cushing disease. A pituary adenoma resulting in excessive production of adrenocorticotropic hormone. This leads to hypersecretion of cortisol by the adrenal glands and ACTH-dependent Cushing syndrome. Clinical manifestations of Cushing syndrome include facial and trunkal obesity, abdominal striae, muscular weakness, osteoporosis, arterial hypertension, diabetes.
Defects in AIP are a cause of prolactin-secreting pituitary adenoma (PSPA) [MIM:600634]; also known as prolactinoma. Prolactin-secreting pituitary adenoma is the most common type of hormonally active pituitary adenoma.
- Sequence similaritiesContains 1 PPIase FKBP-type domain.
Contains 2 TPR repeats.
- Cellular localizationCytoplasm.
- AA408703 antibody
- AH receptor interacting protein antibody
- AH receptor-interacting protein antibody
- AIP antibody
- AIP_HUMAN antibody
- ARA 9 antibody
- Aryl hydrocarbon receptor interacting protein antibody
- Aryl-hydrocarbon receptor-interacting protein antibody
- AW476050 antibody
- D19Bwg1412e antibody
- fa03h10 antibody
- FKBP 16 antibody
- FKBP 37 antibody
- FKBP16 antibody
- FKBP37 antibody
- FLJ20608 antibody
- HBV X associated protein 2 antibody
- HBV X associated protein antibody
- HBV X-associated protein 2 antibody
- HBVX associated protein antibody
- Immunophilin homolog ARA 9 antibody
- Immunophilin homolog ARA9 antibody
- MGC101101 antibody
- SMTPHN antibody
- XAP 2 antibody
- XAP-2 antibody
- XAP2 antibody
Anti-ARA9 antibody - Carboxyterminal end images
Anti-ARA9 antibody - Carboxyterminal end (ab62813) at 0.02 µg/ml + NIH 3T3 cell lysate (in RIPA buffer) at 35 µg
Predicted band size : 40 kDa
Observed band size : 37 kDa (why is the actual band size different from the predicted?)
References for Anti-ARA9 antibody - Carboxyterminal end (ab62813)
ab62813 has not yet been referenced specifically in any publications.